
Investors File Class Action Lawsuit Against Replimune Group
A class action lawsuit has been launched against biotechnology firm Replimune Group, Inc. following a sharp decline in share value. The litigation, filed by Robbins LLP, accuses the company of misleading investors regarding the clinical efficacy and regulatory viability of its lead immunotherapy candidate, RP1.


























